Postherpetic Neuralgia Medication

Updated: Dec 01, 2017
  • Author: W Alvin McElveen, MD; Chief Editor: Robert A Egan, MD  more...
  • Print

Medication Summary

The goal of therapy for postherpetic neuralgia (PHN) is to reduce morbidity through the use of tricyclic antidepressants, anticonvulsants, anesthetics, analgesics, corticosteroids, and antiviral agents. A recently approved vaccine is also effective for preventing herpes zoster (HZ) outbreaks and PHN. A recent trial demonstrated that the combination of gabapentin and nortriptyline was more efficacious than either drug as monotherapy for neuropathic pain. [15] Another study found that a single 60-minute treatment with the high-concentration capsaicin patch NGX-4010 reduced PHN for up to 12 weeks regardless of concomitant systemic neuropathic pain medication use. [16]


Tricyclic antidepressants

Class Summary

Complex group of drugs that have central and peripheral anticholinergic effects as well as sedative effects. They have central effects on pain transmission. They block the active reuptake of norepinephrine and serotonin.

Amitriptyline (Elavil)

By inhibiting reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, may increase synaptic concentration in CNS. Useful as analgesic for certain types of chronic and neuropathic pain.

Nortriptyline (Pamelor, Aventyl HCl)

Has demonstrated effectiveness in treatment of chronic pain; by inhibiting reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, may increase synaptic concentration in CNS; pharmacodynamic effects such as desensitization of adenyl cyclase and down-regulation of beta-adrenergic receptors and serotonin receptors also appear to play role in its mechanisms of action.



Class Summary

Pain control is essential to quality patient care; it ensures patient comfort and promotes pulmonary toilet. Most analgesics have sedating properties, which are beneficial for patients who experience pain.

Capsaicin topical

Natural chemical derived from plants of Solanaceae family. By depleting and preventing reaccumulation of substance P in peripheral sensory neurons, may render skin and joints insensitive to pain. Substance P thought to be chemomediator of pain transmission from periphery to CNS.

Capsaicin 8% transdermal patch (Qutenza)

Transient receptor potential vanilloid-1 (TRPV1) agonist indicated for neuropathic pain associated with postherpetic neuralgia. TRPV1 is an ion channel–receptor complex expressed on nociceptive skin nerve fibers. Topical capsaicin causes initial TRPV1 stimulation that may cause pain, followed by pain relief by reduction in TRPV1-expressing nociceptive nerve endings. Neuropathic pain may gradually recur over several months (thought to be caused by TRPV1 nerve fiber reinnervation of treated area).



Class Summary

These agents have anti-inflammatory properties. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune response to diverse stimuli.


Used to treat various allergic and inflammatory diseases. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and by reversing increased capillary permeability.

Prednisone (Deltasone, Rayos)

Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and by reversing increased capillary permeability.

Methylprednisolone (Solu-Medrol)

Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.


Antiviral agents

Class Summary

The goal of antivirals is to shorten the clinical course, prevent complications, prevent the development of latency and/or subsequent recurrences, decrease transmission, and eliminate established latency.


Pro-drug that, when biotransformed into active metabolite penciclovir, may inhibit viral DNA synthesis/replication.



Class Summary

These agents stabilize the neuronal membrane so the neuron is less permeable to ions. This prevents the initiation and transmission of nerve impulses, thereby producing the local anesthetic action.

Lidocaine anesthetic (Lidoderm 5% patch)

Several recent studies have advocated topical administration of lidocaine as treatment of PHN. Lidocaine gel (5%) in placebo-controlled study showed significant relief in 23 patients studied. Lidocaine tape also decreases severity of pain.



Class Summary

These agents are used to manage severe muscle spasms and provide sedation in neuralgia. They have central effects on pain modulation. Prescribing information for gabapentin products (ie, Neurontin, Gralise, Horizant) describe a statistical improvement in pain scores (ie, a decrease by at least 50% from baseline) compared with placebo when treated for postherpetic neuralgia.

In October 2017, FDA approved Lyrica CR (pregabalin extended-release tablets), a once-daily treatment for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN). The approval was based on data from a randomized placebo-controlled trial conducted in 801 patients with PHN. The trial included a 6-week single-blind, dose optimization phase followed by a 13-week double-blind phase. Compared to placebo, more patients in the Lyrica CR group experienced at least a 50% improvement in pain intensity (73.6% vs. 54.6%). 

Pregabalin (Lyrica, Lyrica CR)

Approved by FDA for use in PHN. Freynhagen et al describe a statistically significant reduction in mean pain score and in pain-related sleep interference compared with placebo. Pregabalin binds with high affinity to alpha2-delta subunit of voltage-gaited calcium channels, thereby reducing excitatory neurotransmitters. Has half-life of approximately 6 h and is eliminated by renal excretion. Decrease in creatinine clearance results in decrease elimination and, therefore, increase in plasma concentration. Peak plasma concentration occurs at one and one half hours after oral intake. Bioavailability is 90%. Following repeated dosing, steady state concentration is achieved at 24-48 h. Can be taken with or without food.

The extend-release formulation is available in 82.5mg, 165mg, and 330mg tablets strength. It is administered once daily after an evening.

Gabapentin (Neurontin, Gralise)

This medication has been approved by the FDA for the treatment of PHN. Has properties common to other anticonvulsants and antineuralgic effects. Exact mechanism of action is not known. Structurally, gabapentin is related to GABA, but it does not interact with GABA receptors. Believed to have a binding site at the alpha 2-delta protein, an auxiliary subunit of voltage-gaited calcium channels. In the rat brain, binding is localized on neuronal dendritic areas. Relevance of these observations to treatment of PHN is not known.

Gabapentin enacarbil (Horizant)

Gabapentin prodrug that provides a longer duration of action compared with gabapentin. Structurally related to neurotransmitter GABA, but has no effect on GABA binding, uptake, or degradation. The mechanism for analgesic activity is unknown. Approved by the FDA for PHN.



Class Summary

These agents are used to induce active immunity.

Zoster vaccine live (Zostavax)

Vaccine conveys active immunity by stimulating production of endogenously produced antibodies. It is indicated for adults ≥50 years, regardless of whether they report prior episodes of herpes zoster; although vaccine is FDA-licensed for patients ≥50 years.

Zoster vaccine recombinant (Shingrix)

Non-live, recombinant subunit vaccine intended for intramuscular injection in 2 doses. It consists of glycoprotein E, an antigen, and AS01B, an adjuvant system, intended to induce a strong and sustained immune response to help overcome reduced immunity that comes with age. Indicated for the prevention of shingles (herpes zoster) in adults aged ≥50 years.